Accessibility StatementSkip Navigation HUDSON, N.H., Nov. 5, 2025 /PRNewswire/ -- BAE Systems' (LON: BA) Compass Call Mission Crew Simulator (CCMCS) for the EA-37B electronic attack mission system has been approved for training by the U.S. Air Force and delivered to support interim fielding. The simulator provides realistic training and mission rehearsal for crews of the EA-37B, the U.S. Department of Defense's only long-range, stand-off, electromagnetic warfare jamming platform. Continue Reading For more i ...

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the "Events†page of the Investors section of the Compass website. A replay of the webcast will ...

Compass, Inc. (COMP) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this company would post earnings of $0.07 per share when it actually produced earnings of $0.07, delivering no surprise.Over the last four quarters, the company has surpasse ...

Scott Wahlers, Chief Financial Officer of Compass, said, "I'm very pleased with our financial and operational execution this quarter, which resulted in record Q3 results. We delivered $1.85 billion in revenue, meeting the high-end of our guidance range, and a robust 23.6% growth year-over-year. Additionally, we generated Adjusted EBITDA of $93.6 million, an increase of 80% from $52 million in the year-ago quarter, which reflects the highest Adjusted EBITDA for any Q3 period, and the second highest quarterly ...

Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months. ...

事件概述 - Compass Wealth Management LLC在2025年10月31日向美国证券交易委员会提交的文件中披露，其新建了Webster Financial的头寸，购买了96,518股，基于2025年第三季度平均股价估算的交易价值为3184万美元 [1] - 此次增持后，该基金的可报告持仓总数达到148个头寸 [1] - 此次建仓使Webster Financial一举成为该基金的最大持仓，WBS持仓价值3180万美元，占其资产管理规模的7.1% [6][7] 公司财务表现 - 公司2025年第三季度营收达到7.326亿美元，高于2024年同期的6.476亿美元 [6] - 公司2025年第三季度稀释后每股收益为1.54美元，较去年同期的1.10美元有所提升 [7] - 截至最近十二个月，公司营收为27.2亿美元，净利润为8.3061亿美元 [3] - 公司股息收益率为2.8% [3] - 基于每股收益增长，公司股票的市盈率约为11倍，估值合理 [9] 公司业务与战略 - Webster Financial是一家区域性银行机构，业务模式多元化，涵盖商业银行、健康储蓄账户管理和零售金融服务 [5] - 公司通过广泛的产品组合和多部门运营方式驱动稳定的收入流，并维持在美国区域银行业中的竞争地位 [5] - 公司业务分为三个部门：商业银行、HSA银行和零售银行，提供了多元化的收入基础 [8] - 公司专注于传统银行业务和专业的HSA服务，使其能够覆盖广泛的客户群体并获得经常性费用收入机会 [5] - 公司服务对象包括个人、家庭、中小型企业以及美国各地的雇主，重点客户是商业客户和HSA账户持有者 [8] 股价表现 - 截至2025年10月30日，Webster Financial股价为56.59美元 [2][3] - 该股价在过去一年中上涨了9%，但表现落后于标普500指数8个百分点 [2]

Accessibility StatementSkip Navigation Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health KEARNY, N.J., Oct. 30, 2025 /PRNewswire/ -- NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care. This collaboration aims to deepen the mechanistic understanding of psychedelic c ...

事件概述 - 全国知名的股东权益律师事务所Bragar Eagel & Squire, P C 正在对Compass Diversified (NYSE: CODI) 展开调查 调查涉及公司董事会是否违背了对公司的 fiduciary duties [1] - 调查源于一项针对Compass的集体诉讼 该诉讼于2025年6月6日提交 类别期为2024年5月1日至2025年5月7日 [1] 诉讼指控详情 - 指控称 在类别期内 被告做出了虚假和/或误导性陈述 和/或未能披露相关信息 [2] - 具体指控包括 公司子公司Lugano Holdings, Inc 存在未记录的融资安排以及销售 销售成本 存货和应收账款方面的 irregularities [2] - 子公司财务报表中的 irregularities 和未披露细节导致公司整体财务报表不可靠 且需要重述 [2] - 公司未能维持与财务报表相关的 adequate internal controls [2] - 因此 被告的公开陈述在所有相关时间点均存在重大虚假和/或误导性 [2]

Oct 29, 2025 6:30 AM Eastern Daylight Time Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors Share LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a par ...

Oct 28, 2025 6:30 AM Eastern Daylight Time Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025 Share Compass management will host a conference call at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an updat ...